Defence Therapeutics Inc. Total Liabilities
Defence Therapeutics Inc. total liabilities. Based on the latest financial reports, Defence Therapeutics Inc. (DTC) has total liabilities worth €2.59 Million EUR (≈ $3.03 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Defence Therapeutics Inc. (DTC) liquidity interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Defence Therapeutics Inc. (2020–2024)
Total liabilities of Defence Therapeutics Inc. from 2020 to 2024. This chart illustrates how Defence Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Defence Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Defence Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mercan Kimya Sanayi ve Ticaret AS
IS:MERCN
|
Turkey | TL1.44 Billion |
|
ReGen III Corp
V:GIII
|
Canada | CA$5.10 Million |
|
Zanaga Iron Ore Company Limited
F:6ZA
|
Germany | €139.00K |
|
Sunlands Technology Group
NYSE:STG
|
USA | $1.10 Billion |
|
TS Corp Preference Shares
KO:001795
|
Korea | ₩777.09 Billion |
|
Zelan Bhd
KLSE:2283
|
Malaysia | RM524.27 Million |
|
Cassius Mining Ltd
AU:CMD
|
Australia | AU$685.20K |
|
Canaf Investments Inc
V:CAF
|
Canada | CA$2.07 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Defence Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see DTC asset base.
Liquidity & Leverage Metrics
Defence Therapeutics Inc. Total Liabilities Ratios Explained
Defence Therapeutics Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.89 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Defence Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Defence Therapeutics Inc. (2020–2024)
The table below shows the annual total liabilities of Defence Therapeutics Inc. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-06-30 | €4.06 Million ≈ $4.75 Million |
+106.55% |
| 2023-06-30 | €1.97 Million ≈ $2.30 Million |
+77.61% |
| 2022-06-30 | €1.11 Million ≈ $1.29 Million |
+805.66% |
| 2021-06-30 | €122.26K ≈ $142.93K |
+152.85% |
| 2020-06-30 | €48.35K ≈ $56.53K |
-- |
About Defence Therapeutics Inc.
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting vario… Read more